Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Lymphoid 1Gastrointestinal 1

Conditions

Muscular Atrophy 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3ER+ and AR+ Breast Cancer 2Triple Negative Breast Neoplasms 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Cachexia 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × ostarine × Clear all
NCT01355497 2020-11-09

Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

GTx

Phase 3 Completed
330 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

NCT01355484 2016-03-03

Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

GTx

Phase 3 Completed
321 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Muscular Atrophy

NCT00467844 2014-07-11

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

GTx

Phase 2 Completed
159 enrolled 11 charts
GastrointestinalLymphoidThoracic

Cachexia, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Muscular Atrophy, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡